Kissei Pharmaceutical Co., Ltd.
KSPHF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $88,330 | $75,579 | $67,493 | $65,381 |
| % Growth | 16.9% | 12% | 3.2% | – |
| Cost of Goods Sold | $44,265 | $38,238 | $284 | $299 |
| Gross Profit | $44,065 | $37,341 | $224 | $238 |
| % Margin | 49.9% | 49.4% | 0.3% | 0.4% |
| R&D Expenses | $0 | $0 | $10,391 | $10,363 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $38,291 | $0 | $20,304 | $19,923 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $33,324 | $2,809 | $2,354 |
| Operating Expenses | $38,292 | $33,324 | $33,504 | $32,640 |
| Operating Income | $5,773 | $4,017 | -$1,129 | -$1,402 |
| % Margin | 6.5% | 5.3% | -1.7% | -2.1% |
| Other Income/Exp. Net | $9,837 | $10,432 | $14,809 | $17,909 |
| Pre-Tax Income | $15,610 | $14,449 | $13,680 | $16,507 |
| Tax Expense | $3,634 | $3,159 | $3,046 | $3,475 |
| Net Income | $11,961 | $11,160 | $10,528 | $12,921 |
| % Margin | 13.5% | 14.8% | 15.6% | 19.8% |
| EPS | 274.21 | 246.58 | 228.31 | 280.2 |
| % Growth | 11.2% | 8% | -18.5% | – |
| EPS Diluted | 274.21 | 246.58 | 228.31 | 280.2 |
| Weighted Avg Shares Out | 44 | 45 | 46 | 46 |
| Weighted Avg Shares Out Dil | 44 | 45 | 46 | 46 |
| Supplemental Information | – | – | – | – |
| Interest Income | $57 | $21 | $23 | $42 |
| Interest Expense | $21 | $18 | $20 | $23 |
| Depreciation & Amortization | $4,615 | $4,254 | $4,109 | $3,730 |
| EBITDA | $20,246 | $18,721 | $2,966 | $2,328 |
| % Margin | 22.9% | 24.8% | 4.4% | 3.6% |